MichaelWerner NikolausDeiningerMD
Hematology • Salt Lake City, UTProfessor, Internal Medicine, University of Utah School of Medicine
Dr. Deininger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1950 Circle Of Hope Dr
Salt Lake City, UT 84112Phone+1 801-213-3800- Is this information wrong?
Education & Training
University of Wurzburg Faculty of MedicineClass of 1990
Certifications & Licensure
CT State Medical License Current
WI State Medical License 2022 - 2025
OR State Medical License 2008 - 2023
UT State Medical License 2010 - 2022
Clinical Trials
- A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Start of enrollment: 2011 Apr 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Start of enrollment: 2014 Jul 08
Publications & Presentations
PubMed
- A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.Qiao, Y., Huang, X., Moos, P., Ahmann, J., Pomicter, A., Marth, G., Deininger, M., Byrd, J., Woyach, J., Stephens, D.> ;Genome Research. 2024 Feb 7
- 2 citationsEuropean LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.Nicholas C P Cross, Thomas Ernst, Susan Branford, Jean-Michel Cayuela, Michael Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Katerina Machova Polakova, Jerald P Rad...> ;Leukemia. 2023 Nov 1
- 4 citationsPevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti A Patel, Maria R Baer, Wendy Stock, Michael Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R ...> ;Blood Advances. 2023 Jun 13
- Join now to see all
Journal Articles
- Functional Genomic Landscape of Acute Myeloid LeukaemiaMarc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
Lectures
- Pregnancy Outcomes in Patients Treated with Bosutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Genotypic Representation of Myelodysplastic/Myeloproliferative Neoplasms in Nrg, Nrg-3GS and Srg-W41 Mice with Transgenic Expression of Human Cytokines2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Versiti Appoints Michael Deininger, MD, PhD, as Executive Vice President, Chief Scientific Officer and Director of Versiti's Blood Research InstituteApril 22nd, 2021- Proteasome 26S Subunit, Non-ATPases 1 (PSMD1) and 3 (PSMD3), Play an Oncogenic Role in Chronic Myeloid Leukemia by Stabilizing Nuclear Factor-Kappa BMarch 12th, 2021
The Chronic Myeloid Leukaemia Story in the United Kingdom Since 1960November 15th, 2020- Join now to see all
Grant Support
- Mechanisms Of Chronic Myeloid Leukemia Progenitor Cell SurvivalNational Cancer Institute2010–2011
- Ivis Spectrum Biophotonics InstrumentNational Center For Research Resources2009
- Biology Of Imatinib-Resistant Mutants Of BCR-ABLNational Heart, Lung, And Blood Institute2005–2009
Hospital Affiliations
Froedtert and the Medical College of Wisconsin Froedtert HospitalMilwaukee, Wisconsin
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
